Pharmacokinetics of ceftazidime after intravenous and intramuscular administration to domestic cats

Veterinary Journal

Volumn 178, Issue 2, 2008, Pages 238-243

  Albarellos, G A ^a   Ambros, L A ^a   Landoni, M F ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Antimicrobials; Cats; Ceftazidime; Cephalosporins; Pharmacokinetics

Indexed keywords

CEFTAZIDIME; COAGULASE;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CAT; COAGULASE NEGATIVE STAPHYLOCOCCUS; COAGULASE POSITIVE STAPHYLOCOCCUS; COMPARTMENT MODEL; DOMESTIC ANIMAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MALE; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; SINGLE DRUG DOSE; STAPHYLOCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CATS; CEFTAZIDIME; CROSS-OVER STUDIES; FEMALE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE;

ESCHERICHIA COLI; FELIS CATUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS;

EID: 54449101720     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2007.06.026     Document Type: Article

References (37)

1. Abd-El-Aty A.M., Goudah A., and Abo-El-Sooud K. Pharmacokinetics, intramuscular bioavailability and tissue residue profiles of ceftazidime in a rabbit model. Deutsche Tierärztliche Wochenschrift 108 (2001) 168-171
2. Albarellos G.A., Bonafine R.R., Kreil V.E., Ambros L.A., Montoya L., and Hallu R.E. A non-surgical jugular catheterization technique for multiple blood sampling in cats. Laboratory Animals 37 (2003) 188-192
3. Armstrong G.C., Wise R., Brown R.M., and Hancox J. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrobial Agents and Chemotherapy 20 (1981) 356-358
4. Baggot J.D. The Physiological Basis of Veterinary Clinical Pharmacology (2001), Blackwell Science Ltd., London, UK p. 45
5. Bennet J.V., Brodie J.L., Bennet E.J., and Kirby W.M. Simplified accurate method for antibiotic assay of clinical specimens. Applied Microbiology 14 (1966) 170-177
6. Carbon C., Dromer F., Brion N., Cremieux A.C., and Contrepois A. Renal disposition of ceftazidime illustrated by interferences by probenecid, furosemide, and indomethacin in rabbits. Antimicrobial Agents and Chemotherapy 26 (1984) 373-377
7. Casellas J.M., Tomé G., Bantar C., Bertolini P., Blázquez N., Borda N., Couto E., Cudmani N., Guerrera J., Juárez M.J., López T., Littvik A., Méndez E., Notario R., Ponce G., Quinteros M., Salamone F., Sparo M., Sutich E., Vaylet S., and Wolff L. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients. Diagnostic Microbiology and Infectious Disease 47 (2003) 527-537
8. CLSI, 2006a. (former NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M07-A5. Wayne (PA), USA.
9. CLSI, 2006b. (former NCCLS). Performance standards for antimicrobial susceptibility testing. Supplemental tables M100-S16. Wayne (PA), USA.
10. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26 (1998) 1-12
11. Deguchi E., and Akuzawa M. Renal clearance or endogenous creatinine, urea, sodium, and potassium in normal cats and cats with chronic renal failure. Journal of Veterinary Medical Science 59 (1997) 509-512
12. Drusano G.L., Standiford H.C., Fitzpatrick B., Leslie J., Tangtatsawasdi P., Ryan P., Tatem B., Moody M.R., and Schimpff S.C. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrobial Agents and Chemotherapy 26 (1984) 388-393
13. Gibaldi M., and Perrier D. Pharmacokinetics. Second ed. (1982), VCH, New York
14. Gunderson B.W., Ross G.H., Ibrahim K.H., and Rotschafer J.C. What do we really know about antibiotic pharmacodynamics?. Pharmacotherapy 21 (2001) 302-318
15. Kemmerich B., Warns H., Lode H., Borner K., Koeppe P., and Knothe H. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrobial Agents and Chemotherapy 24 (1983) 333-338
16. Kessler R.E., Bies M., Buck R.E., Chisholm D.R., Pursiano T.A., Tsai Y.H., Misiek M., Price K.E., and Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 27 (1985) 207-216
17. Kita Y., Yamazaki T., and Imada A. Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals. Antimicrobial Agents and Chemotherapy 36 (1992) 2481-2486
18. Leroy A., Leguy F., Borsa F., Spencer G.R., Fillastre J.P., and Humbert G. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrobial Agents and Chemotherapy 25 (1984) 638-642
19. Matsui H., Komiya M., Ikeda C., and Tachibana A. Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and Rhesus monkeys. Antimicrobial Agents and Chemotherapy 26 (1984) 204-207
20. McKellar Q.A., Sanchez Bruni S.F., and Jones D.G. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 27 (2004) 503-514
21. Moore K.W., Trepanier L.A., Lautzenhiser S.J., Fialkowski J.P., and Rosin E. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa. American Journal of Veterinary Research 61 (2000) 1204-1208
22. Mouton J.W., and den Hollander J.G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy 38 (1994) 931-936
23. ÓCallaghan C.H., Acred P., Harper P.B., Ryan D.M., Kirby S.M., and Harding S.M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrobial Agents and Chemotherapy 17 (1980) 876-883
24. Paradis D., Vallée F., Allard S., Bisson C., Daviau N., Drapeau C., Auger F., and LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrobial Agents and Chemotherapy 36 (1992) 2085-2092
25. Paulfeuerborn W., Müller H.J., Borner K., Koeppe P., and Lode H. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrobial Agents and Chemotherapy 37 (1993) 1835-1841
26. Plumb D.C. Veterinary Drug Handbook. fifth ed. (2005), Blackwell Publishing Professional, Iowa, USA pp. 198-0220
27. Rhomberg P.R., Jones R.N., Sader H.S., and The MYSTIC ProGramme (US) Study Group. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) ProGramme: report of the 2001 data from 15 United States medical centres. International Journal of Antimicrobial Agents 23 (2004) 52-59
28. Rule R., Rubio M., and Perelli M.C. Pharmacokinetics of ceftazidime in sheep and its penetration into tissue and peritoneal fluids. Research in Veterinary Science 51 (1991) 233-238
29. Rule R., Quiroga G.H., Rubio M., Buschiazzo H.O., and Buschiazzo P.M. The pharmacokinetics of ceftazidime in lactating and non-lactating cows. Veterinary Research Communications 20 (1996) 543-550
30. Sakata Y., McCracken G.H., Thomas M.L., and Olsen K.D. Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae Type b. Antimicrobial Agents and Chemotherapy 25 (1984) 29-32
31. Schwartz G. Estimating the dimension of a model. Annals of Statistics 6 (1978) 461-464
32. Soback S., and Ziv G. Pharmacokinetics of ceftazidime given alone and in combination with probenecid to unweaned calves. American Journal of Veterinary Research 50 (1989) 1566-1569
33. Toutain P.L., Del Castillo J.R.E., and Bousquet-Mélou A. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science 73 (2002) 105-114
34. Tsuji M., Ishii Y., Ohno A., Miyazaki S., and Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrobial Agents and Chemotherapy 42 (1998) 94-99
35. Turnidge J.D. The pharmacodynamics of ß-lactams. Clinical Infectious Diseases 27 (1998) 10-22
36. Verhagen C.A., Mattie H., and van Strijen E. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. British Journal of Clinical Pharmacology 37 (1994) 193-197
37. Yamaoka K., Nakagawa T., and Uno T. Application of Akaikés information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmaceutics 6 (1978) 165-175